Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an announcement.
Australian Clinical Labs has disclosed an update to its on-market share buy-back program for its ordinary fully paid shares listed on the ASX under ticker ACL. The filing notes that, as of the latest reporting date, the company continues to execute daily buy-backs as part of a capital management initiative first notified in October 2025.
The update confirms that a total of 5,030,768 shares had been bought back prior to the previous trading day, with an additional 83,136 shares repurchased on that day. The ongoing daily purchases signal the company’s active use of share buy-backs to manage its capital structure, which may support earnings per share and indicate confidence in its valuation for existing shareholders.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is a medical diagnostics company that provides pathology and laboratory testing services across Australia. Its core operations focus on processing clinical tests for healthcare providers, hospitals and patients, positioning it within the broader healthcare and diagnostic services sector on the ASX under the code ACL.
Average Trading Volume: 694,264
Technical Sentiment Signal: Sell
Current Market Cap: A$432.4M
Learn more about ACL stock on TipRanks’ Stock Analysis page.